In 2015, it was reported that 30% of oral anticoagulants prescribed for Medicare patients in the United States were direct oral anticoagulants (DOACs), with dabigatran being a popular choice among cardiologists and internal medicine physicians. This is largely due to the drug's safety and efficacy.
In 2015, it was discovered that 30% of oral anticoagulants prescribed to elderly patients in the US were DOACs, with dabigatran being a preferred choice among cardiologists and internists. This is largely due to the drug's safety profile and clinical benefits.